Quote this publication Share Print

TAGRISSO (osimertinib), tyrosine kinase inhibitor

ONCOLOGY - Update
Opinions on drugs - Posted on Apr 12 2018

Reason for request

Re-assessment of the improvement in actual benefit

Substantial actual benefit and minor improvement compared with chemotherapy combining a platinum salt with pemetrexed in patients who acquired the EGFR T790M mutation during a previous treatment with anti-EGFR TKI.

 

  • TAGRISSO has Marketing Authorisation in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR T790M mutation.
  • The new data affect only patients who acquired the EGFR T790M mutation during their first-line treatment with anti-EGFR TKI. 
  • In this case, progression-free survival was improved compared with platinum-based chemotherapy (absolute gain of 5.7 months) in patients previously treated with an anti-EGFR TKI.
  • No gain in overall survival has been demonstrated to date.
  • The safety profile of osimertinib is more favourable than that of platinum salt-based chemotherapy.

 

 


Actual benefit

Important

-


Improvement in actual benefit

IV (mineur)

-


Therapeutic use

-

Ce produit a fait l'objet d'un avis d'efficience rendu par la commission évaluation économique et santé publique le 12 septembre 2017.

Contact Us

Évaluation des médicaments

See also